Answers are grounded in this paper and cite their sources.
Laboratory study reveals distinct G1/S cell-cycle dynamics induced by EGF versus HRG in breast cancer cells, highlighting ligand-specific control of proliferative fate decisions.
ErbB ligands activate distinct receptor dimers that regulate cell proliferation, but how they influence cell-cycle commitment remains unclear. Here, we show that EGF and HRG induce different modes of G1/S progression in ErbB2-amplified BT474 breast cancer cells. Unexpectedly, HRG, despite activating the more potent ErbB2-ErbB3 heterodimer, failed to accelerate G1/S progression; instead, EGF promoted earlier passage through the restriction point and faster S-phase entry. Mechanistically, EGF drove rapid and coordinated cell-cycle progression through ERK-FOS signaling, whereas HRG induced sustained MYC activity, elevated transcriptional heterogeneity, and caused extensive rewiring of cell-cycle regulatory networks. Together, these findings reveal that ligand-specific ErbB signaling controls not only the timing of cell-cycle entry but also the transcriptional architecture that governs proliferative fate decisions.
No takes yet. Share an insight, caveat, or question.
Febri et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: